Apimeds Pharmaceuticals US, Inc. Announces Reverse Stock Split

Apimeds Pharmaceuticals US, Inc. has announced a reverse stock split of its common stock at a ratio of one-for-ten, effective March 26, 2026. This action, approved by stockholders via written consent on December 1, 2025, will consolidate every ten shares into one. The company filed an information statement on February 26, 2026, and expects the reverse stock split to become effective at 12:01 a.m. Eastern Time on March 26, 2026. Following the split, the common stock will trade on a split-adjusted basis on the NYSE American LLC under the symbol "APUS". A new CUSIP number, 03771D201, will be assigned to the common stock. The company will announce the effectiveness of the reverse stock split in a subsequent filing.